International Cannabinoid Research Society Symposium brings together
leaders in medical marijuana field from around the world
TORONTO, July 7, 2014 /CNW/ - The recent International Cannabinoid
Research Society (ICRS) Symposium, which draws medical researchers from
around the world, shone a light on the need for clinical research and
the importance of jurisdictions such as Canada in the development of
cannabis-based medical products to minimize suffering, treat disease
and improve health, says a Canadian expert on medical marijuana.
"Canada is one of the few countries in the world that allows marijuana
for medical prescription use on a national basis. This gives us a real
opportunity to become a world leader in clinical research in this
field," said Umar Syed, President of Cannmart, a Toronto-based company
awaiting approval to become a Licensed Producer of medical marijuana
under the Government of Canada's new Marijuana for Medical Purposes
Cannmart was among dozens of companies and academic institutions that
attended the four-day ICRS symposium last week near Milan, Italy. The
annual academic symposium allows leading medical researchers from
around the world to share scientific and medical benefits of
cannabinoids, the active ingredients produced by the cannabis plant,
and other related compounds.
Syed said that the latest findings presented at the research symposium
were timely, given regulatory changes introduced last spring in Canada,
under which any number of medical marijuana (cannabis) strains can be
grown and distributed by licensed producers approved by the Government
of Canada rather than by Health Canada itself.
"As more licensed producers are approved by the government to produce
and distribute marijuana for medical purposes, we have the rare
opportunity to create strong partnerships between like-minded
companies, academic institutions and various government agencies to
undertake invaluable clinical research in this area," Syed said. "We
need to pool our resources so that we can build on the existing
pre-clinical work on cannabinoids with more relevant human clinical
studies in order to help patients in need with innovative cannabis
products. Information generated by these studies will also help
healthcare professionals make better decisions for their patients."
Cannmart is currently going through approvals process to become licensed
by Health Canada to produce and distribute medical marijuana.
"We are proposing a novel approach by working with other licensed
producers across the country to best serve patients and physicians,"
said Syed. "While our partnered producers focus on producing the best
quality cannabis, we will focus our efforts on research and education
to ensure medical practitioners and patients understand the safe and
effective use of a wide variety of medical cannabis strains."
Cannmart's philosophy is to focus on customers and their needs. Our
company employs healthcare professionals to provide advice to patients
and their prescribers about proper use of medical cannabis, the various
strains available, and the available scientific evidence on
cannabinoids and their usage. Find us online at cannmart.com.
For further information:
Chief Executive Officer